GeneralConnection.com ➔ Dictionary
Dictionary Search

gossamer

Synonyms

Adjective

1. ethereal

2. delicate, diaphanous

Noun

1. filmy, gauzy, see-through, sheer, transparent, vaporous, cobwebby, thin, gauze

2. netting, veiling, cobweb

3. fibril, filament, strand

Usage
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk - Yahoo Finance
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio Insiders Are Down US$45k But Regain Some Losses - simplywall.st
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Gossamer Bio completes exchange offer for convertible notes - Investing.com
Gossamer Bio final tender results: $72M new notes, 317.6M shares available; $18.95M old notes remain - TradingView
On the Trail With Gossamer Gear's Mirage Ultralight 40L Pack - Field Mag
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strate - GuruFocus
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail - BioSpace
Gossamer Gear Grit 28 Review: Is a 14oz Fastpack for Under $200 Too Good To Be True? - The Trek
What to expect from Gossamer Bio’s late-stage lung disease study - statnews.com
Latham Represents Gossamer Bio Inc in Exchange Offer and Consent Solicitation Transaction - Latham & Watkins LLP
This Lightweight Umbrella Protected Us From Sun, Rain, and Even Hail - The New York Times
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Yahoo Finance
Gossamer Bio Inc. (GOSS) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Return On Assets - lwvtexas.org
Gossamer's inhaled Winrevair rival fails PAH study - FirstWord Pharma
GOSS: Gossamer Bio Concludes Exchange Offer for Convertible Seni - GuruFocus
Gossamer Gear Skala 38 Review - The Trek
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals - Yahoo Finance
How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Gossamer Gear Just Unveiled the Lightest Framed Pack Ever - Backpacker Magazine
The Gossamer Thread: My Life as a Psychotherapist - Psychotherapy.net
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
‘Like a Gossamer Sheet’ | David Shulman, Dahlia Krutkovich - The New York Review of Books
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Yahoo Finance
Gossamer Bio reports topline Phase III PROSERA outcomes for PAH - Clinical Trials Arena
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns - Yahoo Finance
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail - Fierce Biotech
Gossamer Nosedives as Late-Stage Failure Plunges PAH Program Into Uncertainty - BioSpace
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - Yahoo Finance
David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake - TradingView
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Massive recapitalization at Gossamer Bio (NASDAQ: GOSS) could give noteholders majority control - Stock Titan
Gossamer Bio (GOSS) director awarded 115,000 stock options as compensation - Stock Titan
D. E. Shaw (GOSS) discloses 9.5% stake after major exchange offer - Stock Titan
Packing Doesn't Stress Me Out Anymore Thanks to the Organizational Genius of This Travel Backpack - Outside Magazine
Context Capital (GOSS) discloses 48.8M-share, 9.9% stake in Gossamer Bio - Stock Titan
A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PR Newswire
Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback - Yahoo Finance
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS DEADLINE ALERT: Hagens Berman Alerts Gossamer Bio (GOSS) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - PR Newswire
Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters
Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director - Stock Titan
Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral - Yahoo Finance
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - Business Wire
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval - statnews.com
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky - PR Newswire
GOSS FINAL DEADLINE ALERT: Gossamer Bio Investors With - GlobeNewswire
Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178 - Stock Titan
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - PR Newswire
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Yahoo Finance
Gossamer Bio extends early tender date for exchange offer; $181.05M tendered, New Notes up to $72M - TradingView
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - PR Newswire
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & - GlobeNewswire
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman - Morningstar
Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Yahoo Finance
Shareholders who lost money in Gossamer Bio, Inc (NASDAQ: GOSS) Should Contact Wolf Haldenstein Immediately - PR Newswire
Gossamer Bio (GOSS) Loses 85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance
Gossamer Bio (GOSS) director receives 115,000 stock options as board compensation grant - Stock Titan
Director at Gossamer Bio (NASDAQ: GOSS) receives 115K stock options - Stock Titan
How Recent Developments Are Shaping the Gossamer Bio Investment Story - Yahoo Finance
Gossamer Bio (NASDAQ: GOSS) extends early tender deadline in major convertible note exchange - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Gossamer Bio options imply 46.1% move in share price post-earnings - Yahoo Finance
Analysts Remain Bullish on Gossamer Bio (GOSS) Citing Undervaluation - Yahoo Finance
Gossamer Bio (GOSS) Reports Topline Phase 3 Results for Seralutinib in Pulmonary Arterial Hypertension - Yahoo Finance
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline - Yahoo Finance
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - BioSpace
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - Voice of Alexandria
Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Yahoo Finance
Why Analysts Say Gossamer Bio’s Story Is Changing Ahead of Critical Clinical Milestones - Yahoo Finance
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - TradingView
Review: GOSSAMER at TAFE: Theatre Arts For Everyone - BroadwayWorld
Calif. biotech company lays off almost half of staff after 78% stock drop - SFGATE
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of - GlobeNewswire
How Gossamer Gear Made a UL Backpacking Comeback - Field Mag
A Big Test For Seralutinib - Will Gossamer's PAH Data Win Investors' Hearts This Month? - RTTNews
Gossamer Bio’s Phase 3 PROSERA PAH Trial Misses Primary Endpoint Despite Numerical 6MWD Gain - Yahoo Finance
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 9, 2025 - BioSpace
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT: Gossamer Bio (GOSS) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before June 1, 2026 Securities Class Action Deadline - Business Wire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky - Business Wire
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
Latham & Watkins Advises Gossamer Bio in Option Agreement to Acquire Respira Therapeutics - Latham & Watkins LLP
Earnings call transcript: Gossamer Bio Q1 2026 shows revenue beat, EPS miss - Investing.com
INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Patient Enrollment Quality: SueWallSt - PR Newswire
GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - Morningstar
Gossamer Bio receives 90.5% tender in debt exchange offer - Investing.com
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Foreign Language Equivalents
Foreign Language Equivalents of 'gossamer'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
gossamet,   gossame,   gossamor,   gossa,er,   gossamerr,   goossamer,   gpssamer,   gissamer,   gossaer,   gossameer,   gossaamer,   fossamer,   gossamr,   gosamer,   gosaamer,   gossamre,   hossamer,   gsosamer,   gossamrr,   gosdamer,   gossmer,   gossaemr,   ossamer,   gosssmer,   gossamee,   gossaner,   ogssamer,   gosssamer,   gossamwr,   godsamer,   gosasmer,   gossammer,   gossmaer,   gosamer,   ggossamer,   gosssamer,   goasamer,   gssamer
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z